ანოტაცია
Oral medication frequently fails in advanced Parkinson's disease (PD), necessitating a prompt switch to device-aided therapies (DAT) such as DBS, LCIG, or CSAI. Current DAT initiation techniques, however, continue to be non-individualized, reactive, and delayed. We offer a useful, phenotype-aligned, milestone-driven model to help choose therapies based on the unique paths of each patient. We created a decision framework and scoring checklist based on patient subtypes and clinical milestones by incorporating ideas from important literature. Three primary PD phenotypes: tremor-dominant, PIGD, and cognitive decline - are correlated with five milestone-based clinical indicators. Our structured model allows for more accurate and timely DAT initiation by striking a balance between treatment efficacy, invasiveness, and contraindications. A decision tree and scoring matrix provide a visual summary of the framework, maximizing its practicality. This framework supports multidisciplinary collaboration and shared decision-making, enhancing patient outcomes by providing structured yet flexible approach to advanced PD management.
წყაროები
Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008 Apr 1;79(4):368–76.
Schröter N, Sajonz BEA, Jost WH, Rijntjes M, Coenen VA, Groppa S. Advanced therapies in Parkinson’s disease: an individualized approach to their indication. J Neural Transm. 2024;131(11):1285–93.
Dijk JM, Espay AJ, Katzenschlager R, de Bie RMA. The Choice Between Advanced Therapies for Parkinson’s Disease Patients: Why, What, and When? J Park Dis. 10(Suppl 1):S65–73.
Mouchaileh N, Cameron J. Device-assisted therapies for Parkinson disease. Aust Prescr. 48(1):10–7.
Medical and surgical management of advanced Parkinson’s disease - Antonini - 2018 - Movement Disorders - Wiley Online Library [Internet]. [cited 2025 Apr 15]. Available from: https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.27340
Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB. Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression. Brain. 2017 Jul 1;140(7):1959–76.
Nijhuis FAP, Schippers B, Bloem BR, Post B, Meinders MJ. A decision aid is not the quick fix for improving shared decision-making in advanced Parkinson’s disease: results of a mixed methods feasibility study. J Neurol. 2025 Mar 13;272(4):269.
